ReviewAmerican journal of respiratory and critical care medicine2022
A Pandemic Lesson for Global Lung Diseases: Exacerbations Are Preventable.
Review in American journal of respiratory and critical care medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Differences in Biologic Clinical Trials for Chronic Rhinosinusitis With Nasal Polyps-Are We Comparing Apples With Oranges?International forum of allergy & rhinology · 2026Review
- Worsening Asthma Outcomes in Australian Adults: A Comparison of Stratified Sample Surveys in 2012 and 2021.The Medical journal of Australia · 2026Article
- Frailty combined with nutritional risk for predicting stroke-associated pneumonia: a cohort study based on a nomogram model.Frontiers in neurology · 2026Article
- Shifting Epidemiology of Atopic Dermatitis in Korean Children: Clinical and Public Health Perspectives.Allergy, asthma & immunology research · 2025Article
- Changing Epidemiology of Pediatric Pulmonary Exacerbations in Cystic Fibrosis.Pediatric pulmonology · 2025Article
- Early Diagnosis of Pneumonia and Chronic Obstructive Pulmonary Disease with a Smart Stethoscope with Cloud Server-Embedded Machine Learning in the Post-COVID-19 Era.Biomedicines · 2025Article
- Change in exacerbation rate of COPD patients before and after COVID-19 infection.Scientific reports · 2025Article
- Triple Therapy in COPD in Real Life: Is It Better to Use Single or Multiple Inhalers?Journal of clinical medicine · 2024Article
- Lipid-Laden Macrophages in Pulmonary Diseases.Cells · 2024Review
- Respiratory pathogen and clinical features of hospitalized patients in acute exacerbation of chronic obstructive pulmonary disease after COVID 19 pandemic.Scientific reports · 2024Article
- Pan-antiviral effects of a PIKfyve inhibitor on respiratory virus infection in human nasal epithelium and mice.Antimicrobial agents and chemotherapy · 2024Article
- Characterization and inhibition of inflammasome responses in severe and non-severe asthma.Respiratory research · 2023Article
- Predicting the RSV Surge: Pediatric RSV Patterns of the COVID Pandemic.The Pediatric infectious disease journal · 2023Article
- Exacerbations of COPD.Respiratory care · 2023Article
- Do upper respiratory viruses contribute to racial and ethnic disparities in emergency department visits for asthma?The Journal of allergy and clinical immunology · 2023Article
- Age-dependent rebound in asthma exacerbations after COVID-19 lockdown.The journal of allergy and clinical immunology. Global · 2022Article
- Characteristics of 12-Month Readmission for Hospitalized Patients with COPD: A Propensity Score Matched Analysis of Prospective Multicenter Study.International journal of chronic obstructive pulmonary disease · 2022Article
- Changes in virus-related exacerbations of chronic respiratory diseases before and after the relaxation of COVID-19 infection control measures: a single-centre retrospective study in Japan.Therapeutic advances in infectious diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
A dramatic global reduction in the incidence of common seasonal respiratory viral infections has resulted from measures to limit the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the pandemic. This has been accompanied by falls reaching 50% internationally in the incidence of acute exacerbations of preexisting chronic respiratory diseases that include asthma, chronic obstructive pulmonary disease, and cystic fibrosis. At the same time, the incidence of acute bacterial pneumonia and sepsis has fallen steeply worldwide. Such findings demonstrate the profound impact of common respiratory viruses on the course of these global illnesses. Reduced transmission of common respiratory bacterial pathogens and their interactions with viruses appear also as central factors. This review summarizes pandemic changes in exacerbation rates of asthma, chronic obstructive pulmonary disease, cystic fibrosis, and pneumonia. We draw attention to the substantial body of knowledge about respiratory virus infections in these conditions, and that it has not yet translated into clinical practice. Now that the large scale of benefits that could be gained by managing these pathogens is unmistakable, we suggest that the field merits substantial academic and industrial investment. We consider how pandemic-inspired measures for prevention and treatment of common infections should become a cornerstone for managing respiratory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.